Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Current Investments (2021 - 2025)

Krystal Biotech's Cash & Current Investments history spans 5 years, with the latest figure at $827.8 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 38.54% year-over-year to $827.8 million; the TTM value through Dec 2025 reached $827.8 million, up 38.54%, while the annual FY2025 figure was $827.8 million, 38.54% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $827.8 million at Krystal Biotech, up from $731.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $827.8 million in Q4 2025 and bottomed at $343.1 million in Q3 2021.
  • The 5-year median for Cash & Current Investments is $504.8 million (2023), against an average of $512.5 million.
  • The largest annual shift saw Cash & Current Investments decreased 19.38% in 2023 before it skyrocketed 53.62% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $438.1 million in 2021, then dropped by 13.45% to $379.2 million in 2022, then surged by 40.35% to $532.2 million in 2023, then rose by 12.28% to $597.5 million in 2024, then soared by 38.54% to $827.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Cash & Current Investments are $827.8 million (Q4 2025), $731.1 million (Q3 2025), and $682.0 million (Q2 2025).